Clofenciclan

Clofenciclan is a psychoactive drug and research chemical of the piperidine chemical class that produces dissociative, hallucinogenic and stimulant effects when administered. It has been sold online as a designer drug. It acts as a potent and selective dopamine reuptake inhibitor (DRI) and a weak serotonin reuptake inhibitor (SRI).

Chemistry[edit | edit source]

Clofenciclan is a piperidine derivative, which is a class of compounds with a diverse range of pharmacological properties. The piperidine chemical structure is found in many synthetic drugs with different pharmacological properties, including stimulant, antidepressant, antipsychotic, analgesic, opioid, and antihistamine effects.

Pharmacology[edit | edit source]

Clofenciclan acts as a potent and selective dopamine reuptake inhibitor (DRI) and a weak serotonin reuptake inhibitor (SRI). This means it effectively increases the levels of the neurotransmitters dopamine and serotonin in the brain by inhibiting their reuptake into neurons. This leads to increased neuronal signaling and subsequent psychoactive effects.

Effects[edit | edit source]

The effects of Clofenciclan can vary greatly depending on the dose and individual's physiology. However, common effects can include euphoria, dissociation, hallucinations, and increased energy. Due to its stimulant effects, it can also lead to increased heart rate and blood pressure, which can be dangerous in individuals with pre-existing heart conditions.

Legal Status[edit | edit source]

The legal status of Clofenciclan varies by country. In some countries, it is a controlled substance, while in others it is completely legal. It is important to check the legal status in your country before purchasing or using this substance.

See Also[edit | edit source]

Clofenciclan Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.